06/02/2026 Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
The Ministry of Health’s Drug Advisory Committee has recommended:
Funding status
RAsciminib 20 mg and 40 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
NRMAF assistance does not apply to asciminib 100 mg tablet.
Clinical indication, subsidy class and MediShield Life claim limit for asciminib are provided in the Annex.